Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing
Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy. Houston, May 25, 2021 – Asylia Therapeutics, Inc. (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the closing of a $14.5 …
Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing Read More »